SCHEMBL29987129

SCHEMBL29987129

O=C(O)Cc1cccc(Br)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.43
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
AKR1B1 P15121 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
PDE5A O76074 1/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
GABRA5 P31644 1/20 0.39
GABRB2 P47870 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 1/20 0.37
PARP1 P09874 1/20 0.37
CTSA P10619 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2730766 1.00 FAAH (0.43) FAAHALDH1A1HPGDAKR1B1TDP1
SCHEMBL28126596 0.86 FAAH (0.41) FAAHALDH1A1HPGDTDP1KDM4E
SCHEMBL4495296 0.85 AKR1B1 (0.48) AKR1B1TDP1PDE5AKDM4ESMN1; SMN2
SCHEMBL6564804 0.82 NPSR1 (0.43) FAAHALDH1A1HPGDKDM1AMAOA
SCHEMBL31715510 0.82 NPSR1 (0.43) FAAHALDH1A1HPGDKDM1AMAOA
SCHEMBL13155513 0.82 FAAH (0.40) FAAHALDH1A1HPGDKDM1AMAOA
Hydrochloric Acid SCHEMBL31026892 0.81 GRIN2D (0.39) FAAHALDH1A1HPGDKDM1AMAOA
SCHEMBL7445471 0.81 KEAP1 (0.44) FAAHALDH1A1HPGDKDM4EKDM1A
Hydrochloric Acid SCHEMBL27699619 0.80 KDM4E (0.46) FAAHALDH1A1HPGDTDP1KDM4E
SCHEMBL7437586 0.78 SMN1; SMN2 (0.47) FAAHALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2022206888-A1 CDK2 INHIBITORS AND USE THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 FAAH 3678/4885ALDH1A1 3745/4885HPGD 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.